Angiographic predictors of 2‐year stent thrombosis in patients receiving drug‐eluting stents: Insights from the ADAPT‐DES study
- 27 January 2016
- journal article
- research article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 89 (1) , 26-35
Abstract
Objectives: We sought to identify angiographic predictors of 2‐year stent thrombosis (ST) in the ADAPT‐DES study.Background: A strong relationship between platelet reactivity and ST after implantation of drug‐eluting stents (DES) was recently confirmed in the prospective, multicenter ADAPT‐DES study.Methods: In a pre‐specified analysis of patients enrolled in ADAPT‐DES, an independent angiographic core laboratory performed detailed angiographic analyses for all cases of ST. Patients with Academic Research Consortium definite/probable target‐lesion ST were matched with controls in a 1:2 ratio, and multivariable Cox regression models identified angiographic predictors of 2‐year ST.Results: Among 8,582 patients who had successful percutaneous coronary intervention (PCI) and were included in the ADAPT‐DES study, 92 (1.1%) patients had ST at 2‐year follow‐up. Target lesion‐related ST was identified in 77 patients (82 lesions) who were clinically matched with 153 patients (196 lesions) without ST. Patients with ST were more likely to have longer target lesions, thrombus, moderate/severe calcification, American College of Cardiology/American Heart Association (ACC/AHA) type C lesions, and saphenous vein grafts. After adjustment for clinical covariates the angiographic variables that predicted ST were lesion complexity (ACC/AHA type C lesion, adjusted HR: 1.97, 95% CI: 1.19 to 3.26, P = 0.01) and presence of thrombus on index PCI (HR: 2.25, 95% CI: 1.40 to 3.59, P < 0.01).Conclusions: Anatomically complex lesions and the presence of thrombus are strong predictors of 2‐year ST in the DES era.Keywords
Funding Information
- ADAPT-DES was sponsored by CRF with research support from Boston Scientific, Abbott Vascular, Medtronic, Cordis, Biosensors, The Medicines Company, Daiichi Sankyo, Eli Lilly, Volcano, and Accumetrics
This publication has 40 references indexed in Scilit:
- Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysisThe Lancet, 2012
- Stent ThrombosisJACC, 2010
- Comparisons of Baseline Demographics, Clinical Presentation, and Long-Term Outcome Among Patients With Early, Late, and Very Late Stent Thrombosis of Sirolimus-Eluting StentsCirculation, 2010
- Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind studyThe Lancet, 2010
- Predictors of Coronary Stent ThrombosisJACC, 2009
- Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trialThe Lancet, 2009
- Drug-Eluting Stent ThrombosisJACC, 2008
- Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting StentsNew England Journal of Medicine, 2007
- Correlates and Long-Term Outcomes of Angiographically Proven Stent Thrombosis With Sirolimus- and Paclitaxel-Eluting StentsCirculation, 2006
- Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting StentsJAMA, 2005